shortagewatch

Home / Companies / Johnson & Johnson

Company family · HQ US

Johnson & Johnson: medicine shortages

JNJ · NYSE

As of 2 Nov 2026, 75 Johnson & Johnson products have a reported shortage across 11 countries, covering 19 medicines.

Products short75rank #26 of 464
Medicines19active ingredients
Countries11/16
New in 90 days10+6 vs market pace
Typical duration13 monthsmedian so far
Manufacturing24%demand-driven 30%

Where

United States10Canada33Germany1Italy9Spain1Austria4Belgium5Switzerland1Czechia2Sweden1Japan8

Which therapeutic classes

Nervous system26Blood19Anti-infectives12Genito-urinary system and sex hormones9Digestive tract and metabolism6Cancer and immune system3

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Johnson & JohnsonJohnson & Johnson: Manufacturing problem 8 (12%)12%Johnson & Johnson: Increased demand 10 (15%)15%Johnson & Johnson: Other 6 (9%)9%Johnson & Johnson: Not stated 42 (64%)64%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

01235Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 5MayJun: 2Jul: 0Aug: 1AugSep: 3Oct: 1Nov: 0NovDec: 0Jan ’26: 1Feb: 3FebMar: 0Apr: 2May: 0MayJun: 2Jul: 0Aug: 2AugSep: 2Oct: 4Nov: 2Nov

Long-run trend in Canada

Canada dashboard
0257102017: 2220172018: 2220182019: 2220192023: 7720232024: 2220242025: 2220252026: 4420262027: 222027

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Johnson & Johnson75

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Johnson & Johnson: 75 / 19Johnson & Johnson

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Erythropoietin184 Jun 2024Not stated6/16
Fentanyl92 May 2025Quality problem or recall9/16
Methylphenidate726 Jul 2023Not stated9/16
Darunavir5not givenNot stated4/16
Itraconazole427 Feb 2026Not stated11/16
Norgestimate and Ethinylestradiol4not givenNot stated1/16
Paliperidone43 Nov 2026Manufacturing problem11/16
Topiramate431 Aug 2026Manufacturing problem8/16
Metformin and Canagliflozin321 Sep 2026Not stated2/16
Progestogens and Estrogens, Sequential Preparations3not givenNot stated1/16
Etravirine228 Apr 2026Not stated1/16
Golimumab210 Aug 2026Other5/16
Norethisterone2not givenNot stated1/16
Rabeprazole22 Nov 2026Increased demand5/16
Risperidone227 Oct 2026Not stated13/16
Canagliflozin11 Jan 2026Other2/16
Emtricitabine, Tenofovir Alafenamide, Darunavir and Cobicistat129 Jun 2026Other1/16
Ibrutinib120 Jun 2026Not stated1/16
Rivaroxaban118 Sep 2026Not stated13/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.